ZFIN ID: ZDB-FIG-130320-28
Choi et al., 2013 - In vivo monitoring of cardiomyocyte proliferation to identify chemical modifiers of heart regeneration. Development (Cambridge, England)   140(3):660-666 Full text @ Development
ADDITIONAL FIGURES
EXPRESSION / LABELING:
Genes:
Fish:
Condition:
Anatomical Term:
Stage: Day 4
PHENOTYPE:
Fish:
Conditions:
Observed In:
Stage: Day 4

Fig. 2 Hedgehog and Igf signaling promote embryonic cardiomyocyte proliferation in zebrafish. (A) Small molecule screen to identify signaling pathways that affect cardiomyocyte (CM) proliferation between 3 and 4 dpf. Green bars, drugs that were identified as potential enhancers of proliferation; red bars, drug that was identified as a potential inhibitor. Data are represented as mean±s.e.m. n=8-12 embryos per condition. In the schematic, green and red circles represent proliferating and non-proliferating cells, respectively. (B) Representative maximum intensity projections of 4 dpf cmlc2:FUCCI embryos treated with Smoothened agonist (SAG) or the Igf agonist NBI-31772. Scale bars: 50 μm. Anterior is to the left in images. (C) Effects of treatments with SAG (5 μM), CyA (5 μM), NBI-31772 (2.5 μM), NVP AEW541 (5 μM) and SB-431542 (5 μM) on cardiomyocyte proliferation signals. n=30-48, mean±s.e.m. *P<0.005, Student′s t-test. Experiments for an individual graph were performed on a combined pool of embryos. Proliferation indices could vary between pools used for each individual graph. (D) Changes in proliferation were reflected by analogous changes in the total number of cardiomyocytes in cmlc2:nucDsRed2 embryos at 4 dpf. n=23-35, mean±s.e.m. *P<0.05, Student′s t-test.

Gene Expression Details
Gene Antibody Fish Conditions Stage Anatomy Assay
mCherry pd57Tg/+; pd58Tg/+ control Day 4 cardiac muscle cell IFL
pd57Tg/+; pd58Tg/+ chemical treatment: pharmaceutical Day 4 cardiac muscle cell IFL
pd57Tg/+; pd58Tg/+ chemical treatment: pharmaceutical Day 4 cardiac muscle cell IFL
Venus pd57Tg/+; pd58Tg/+ control Day 4 cardiac muscle cell IFL
pd57Tg/+; pd58Tg/+ chemical treatment: pharmaceutical Day 4 cardiac muscle cell IFL
pd57Tg/+; pd58Tg/+ chemical treatment: pharmaceutical Day 4 cardiac muscle cell IFL
Antibody Labeling Details No data available
Phenotype Details
Fish Conditions Stage Phenotype
pd57Tg/+; pd58Tg/+ chemical treatment: Cyclopamine Day 4 heart has fewer parts of type cardiac muscle cell, abnormal
pd57Tg/+; pd58Tg/+ chemical treatment: pharmaceutical Day 4 heart has extra parts of type cardiac muscle cell, abnormal
pd57Tg/+; pd58Tg/+ chemical treatment: inhibitor Day 4 heart has fewer parts of type cardiac muscle cell, abnormal
pd57Tg/+; pd58Tg/+ chemical treatment: pharmaceutical Day 4 heart has extra parts of type cardiac muscle cell, abnormal
Acknowledgments:
ZFIN wishes to thank the journal Development (Cambridge, England) for permission to reproduce figures from this article. Please note that this material may be protected by copyright. Full text @ Development